Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Core Insights - Aspire Biopharma Holdings, Inc. is focusing on the commercialization of high-value approved drugs in multi-billion-dollar markets through its innovative sublingual drug delivery technology [1] Company Focus - The company is prioritizing the reformulation of approved drugs to enhance their market potential and accelerate commercialization efforts [1] - Aspire is targeting specific therapeutic areas for future platform expansion, including Central Nervous System (CNS) disorders, men's health, and anti-nausea treatments [1] Pipeline Progress - Key milestones are expected to be achieved through the remainder of 2025 and early 2026, indicating a strategic timeline for the company's development efforts [1]